{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:59:17Z","timestamp":1776214757614,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This post hoc analysis used phase 3 trial data from patients with AS receiving tofacitinib 5\u00a0mg twice daily or placebo to week (W)16; all patients received open-label tofacitinib W16\u201348. Outcomes: nocturnal pain; total back pain; fatigue, spinal pain, peripheral joint pain\/swelling, enthesitis, and morning stiffness (Bath AS Disease Activity Index [BASDAI] questions 1\u20136); BASDAI total score; AS Disease Activity Score (ASDAS). Median time to improvement events was estimated using non-parametric Kaplan-Meier models. Improvement events were defined as initial (first post-baseline observation) and continued (sustained for 2 consecutive visits)\u2009\u2265\u200930% and \u2265\u200950% improvement in back\/nocturnal pain or BASDAI questions\/total scores, or ASDAS improvement\u2009\u2265\u20091.1 and \u2265\u20092.0 points.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>269 patients (tofacitinib: <jats:italic>n<\/jats:italic>\u2009=\u2009133; placebo-to-tofacitinib: <jats:italic>n<\/jats:italic>\u2009=\u2009136) were assessed. Median time to improvement was shorter, and more patients experienced improvements with tofacitinib vs. placebo-to-tofacitinib; differences observed from W2 (first post-baseline assessment). Median time to initial (continued)\u2009\u2265\u200930% pain improvement was 4 (4\u20138) weeks for tofacitinib vs. 24 (24) weeks for placebo-to-tofacitinib (8 [8] weeks post-switch). Median time to initial (continued)\u2009\u2265\u200950% improvement of pain, peripheral joint pain\/swelling and enthesitis, morning stiffness, BASDAI total score, and fatigue was 8\u201324 (12\u201340) weeks with tofacitinib vs. 24\u201332 weeks (32 weeks\u2013not estimable [NE]) with placebo-to-tofacitinib. Median time to initial (continued) ASDAS improvement\u2009\u2265\u20091.1 points was 4 (8) weeks for tofacitinib vs. 24 (24) weeks for placebo-to-tofacitinib, and NE for improvement\u2009\u2265\u20092.0 points with either treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Improvements in AS core domains occurred more rapidly with tofacitinib vs. placebo-to-tofacitinib. Half of tofacitinib-treated patients with AS will likely experience improvements\u2009\u2265\u200930% in pain and \u2265\u20091.1 points in ASDAS during month (M)1, \u2265 50% improvement in nocturnal pain and enthesitis by M2, and in morning stiffness by M3. Results show that initiating tofacitinib as soon as possible is associated with quicker improvements in AS core domains vs. delaying treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, NCT03502616, 11 April 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-024-03313-w","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T20:20:54Z","timestamp":1716582054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Bushmakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihane","family":"Rammaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"3313_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","volume":"51","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Boel A, Boonen A, Mease P, Landew\u00e9 R, Kiltz U, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021;51:1342\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 3","key":"3313_CR2","doi-asserted-by":"publisher","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8\u201318.","journal-title":"Ann Rheum Dis"},{"key":"3313_CR3","first-page":"263","volume":"36","author":"R Bohn","year":"2018","unstructured":"Bohn R, Cooney M, Deodhar A, Curtis JR, Golembesky A. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol. 2018;36:263\u201374.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 4","key":"3313_CR4","first-page":"1278","volume":"33","author":"I \u017dagar","year":"2021","unstructured":"\u017dagar I, Delimar V, \u010cota S, \u0160poljari\u0107 Carevi\u0107 S, Kova\u010d Durmi\u0161 K, Lakta\u0161i\u0107 \u017derjavi\u0107 N, et al. The impact of disease activity on quality of life, fatigue, functional status and physical activity in patients with ankylosing spondylitis. Psychiatr Danub. 2021;33(Suppl 4):1278\u201383.","journal-title":"Psychiatr Danub"},{"key":"3313_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-020-00932-5","volume":"22","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou E, Ramiro S. Work disability in axial spondyloarthritis. Curr Rheumatol Rep. 2020;22:55.","journal-title":"Curr Rheumatol Rep"},{"key":"3313_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71:1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 9","key":"3313_CR7","first-page":"0542","volume":"74","author":"S Ramiro","year":"2022","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update [abstract]. Arthritis Rheumatol. 2022;74(Suppl 9):0542.","journal-title":"Arthritis Rheumatol"},{"key":"3313_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"3313_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"3313_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80:1004\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"3313_CR11","doi-asserted-by":"publisher","first-page":"POS0305","DOI":"10.1136\/annrheumdis-2022-eular.2391","volume":"81","author":"L Gossec","year":"2022","unstructured":"Gossec L, Cella D, Walsh JA, Sengupta R, Bushmakin AG, Cappelleri JC, et al. Time to improvement of fatigue in patients with ankylosing spondylitis in a study of tofacitinib [abstract]. Ann Rheum Dis. 2022;81(Suppl 1):POS0305.","journal-title":"Ann Rheum Dis"},{"key":"3313_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"3313_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","journal-title":"J Pain"},{"issue":"Suppl 11","key":"3313_CR14","first-page":"S47","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S47\u201358.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3313_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/rheumatology\/38.9.878","volume":"38","author":"A Calin","year":"1999","unstructured":"Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford). 1999;38:878\u201382.","journal-title":"Rheumatology (Oxford)"},{"key":"3313_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18\u201324.","journal-title":"Ann Rheum Dis"},{"key":"3313_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"PM Machado","year":"2018","unstructured":"Machado PM, Landew\u00e9 R, Heijde DV. Assessment of SpondyloArthritis international society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77:1539\u201340.","journal-title":"Ann Rheum Dis"},{"key":"3313_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/0471602396","volume-title":"Biostatistics: a methodology for the health sciences","author":"G van Belle","year":"2004","unstructured":"van Belle G, Fisher LD, Heagerty PJ, Lumley T. Biostatistics: a methodology for the health sciences. 2nd ed. New York: Wiley; 2004.","edition":"2"},{"key":"3313_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","volume":"143","author":"JT Rich","year":"2010","unstructured":"Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010;143:331\u20136.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"3313_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40744-017-0066-2","volume":"4","author":"M Garrido-Cumbrera","year":"2017","unstructured":"Garrido-Cumbrera M, Hillmann O, Mahapatra R, Trigos D, Zajc P, Weiss L, et al. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients. Rheumatol Ther. 2017;4:219\u201331.","journal-title":"Rheumatol Ther"},{"key":"3313_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40744-023-00570-0","volume":"10","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Navarro-Comp\u00e1n V, Magrey M, Bushmakin AG, Cappelleri JC, Yndestad A, et al. Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis. Rheumatol Ther. 2023;10:1073\u201387.","journal-title":"Rheumatol Ther"},{"key":"3313_CR22","doi-asserted-by":"publisher","first-page":"e002253","DOI":"10.1136\/rmdopen-2022-002253","volume":"8","author":"V Navarro-Comp\u00e1n","year":"2022","unstructured":"Navarro-Comp\u00e1n V, Wei JCC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, et al. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022;8:e002253.","journal-title":"RMD Open"},{"key":"3313_CR23","doi-asserted-by":"publisher","first-page":"e001609","DOI":"10.1136\/rmdopen-2021-001609","volume":"7","author":"K de Vlam","year":"2021","unstructured":"de Vlam K, Ogdie A, Bushmakin AG, Cappelleri JC, Fleischmann R, Taylor PC, et al. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open. 2021;7:e001609.","journal-title":"RMD Open"},{"key":"3313_CR24","doi-asserted-by":"publisher","first-page":"e002049","DOI":"10.1136\/rmdopen-2021-002049","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Ostor AJK, Mease PJ, Tillett W, Baraliakos X, de Vlam K, et al. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open. 2022;8:e002049.","journal-title":"RMD Open"},{"key":"3313_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13075-022-02721-0","volume":"24","author":"DD Gladman","year":"2022","unstructured":"Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, et al. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022;24:40.","journal-title":"Arthritis Res Ther"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03313-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03313-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03313-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T20:30:23Z","timestamp":1716582623000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03313-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3313"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03313-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines, local regulatory requirements, and the ethical principles of the Declaration of Helsinki. Patients provided written informed consent, and the study protocol was approved by an Institutional Review Board or Independent Ethics Committee at each study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VN-C has received grant\/research support from AbbVie and Novartis, has acted as a consultant\/speaker for, or has received honoraria from, AbbVie, Eli Lilly, Fresenius Kabi, Janssen, MoonLake, MSD, Novartis, Pfizer Inc, and UCB. AD has received grant\/research support from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Galvani, Janssen, Novartis, Pfizer Inc, and UCB, has acted as a consultant for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer Inc, and UCB, and has acted as a speaker for, or has received honoraria from, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. RB has received grant\/research support from AbbVie, Janssen, Novartis, and Pfizer Inc, has acted as a consultant for AbbVie, Pfizer Inc, and Roche, has acted as a speaker for, or has received honoraria from, AbbVie, Cooper Maroc, Hikma, Janssen, Novartis, Pfizer Inc, Phi, Roche, and Sothema, and has been an advisor or review panel member for AbbVie, Janssen, Hikma, Newbridge, Novartis, Pfizer Inc, Roche, and Sothema. AGB, JCC, and JR are employees and stockholders of Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}